SCHEMBL2543395

SCHEMBL2543395

CCOc1cc([N+](=O)[O-])c(C(N)=O)cc1NC(C)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 2/20 0.52
GALR2 O43603 1/20 0.52
MITF O75030 1/20 0.52
POLB P06746 1/20 0.52
HSP90AA1 P07900 1/20 0.52
HPGD P15428 1/20 0.52
XBP1 P17861 1/20 0.52
CCR6 P51684 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KMT2A Q03164 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 2/20 0.44
EGFR P00533 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2535876 0.88 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL28497946 0.85 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL28499292 0.82 LMNA (0.48) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL9793657 0.79 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL5951849 0.78 KMT2A (0.53) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL8178297 0.76 AKR1C3 (0.50) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL3266479 0.76 SMN1; SMN2 (0.60) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL3266352 0.75 LMNA (0.55) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL9721603 0.75 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2LMNAGALR2MITF
SCHEMBL11591274 0.74 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MITFHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481741-B2 Preparation methods of 6 substituted amino-3 cyanoquinoline compounds and the intermediates thereof TOPHARMAN SHANGHAI CO., LTD. (CN) 2013-07-09 US disclosed
US-20110263860-A1 PREPARATION METHODS OF 6-SUBSTITUTED AMINO-3-CYANOQUINOLINE COMPOUNDS AND THE INTERMEDIATES THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263860-A1 PREPARATION METHODS OF 6-SUBSTITUTED AMINO-3-CYANOQUINOLINE COMPOUNDS AND THE INTERMEDIATES THEREOF QPCT, CBR3, KCNQ2 ALDH1A1 772/4885SMN1; SMN2 4702/4885LMNA 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.